CHAL 36-Overview of pharmaceutical patent-ANDA litigation under the Hatch-Waxman Act

被引：0

作者：

Hasford, Justin J. ^{[1
]}

机构：

[1] Finnegan Henderson Farabow Garrrett & Dunner LLP, Washington, DC 20001 USA

来源：

ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2007年 / 233卷

关键词：

D O I：

暂无

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

36-CHAL

引用

页码：901 / 901

页数：1

共 18 条

[1] Patent litigation under the Hatch-Waxman Act
Cyr, Shana
[J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2019, 257
[2] Inducing patent infringement in Hatch-Waxman ANDA litigation
Main, Denise
[J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 244
[3] CHAL 12 - FTC scrutiny of patent settlements in Hatch-Waxman cases
McKithen, Marc
[J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2009, 237 : 953 - 953
[4] The Hatch-Waxman Act during patent prosecution and beyond
Mahn, TG
[J]. FOOD AND DRUG LAW JOURNAL, 1999, 54 (02) : 233 - 236
[5] Patent term extensions for human drugs under the US Hatch-Waxman Act
Boone, Jeffrey S.
[J]. JOURNAL OF INTELLECTUAL PROPERTY LAW & PRACTICE, 2009, 4 (09) : 658 - 664
[6] Continuing Abuse of the Hatch-Waxman Act by Pharmaceutical Patent Holders and the Failure of the 2003 Amendments
Avery, Matthew
[J]. HASTINGS LAW JOURNAL, 2008, 60 (01) : 171 - +
[7] Litigation under the Hatch Waxman Act.
Stack, S
[J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2004, 228 : U397 - U397
[8] Rational Antitrust Policy and Reverse Payment Settlements in Hatch-Waxman Patent Litigation
Opderbeck, David W.
[J]. GEORGETOWN LAW JOURNAL, 2010, 98 (05) : 1303 - 1348
[9] Overview of the Hatch-Waxman Act and its impact on the drug development process
Mossinghoff, GJ
[J]. FOOD AND DRUG LAW JOURNAL, 1999, 54 (02) : 187 - 194
[10] CHAL 11 - Patents, competition, antitrust and generic drugs: Resolving Hatch-Waxman Act issues
Drake, Kirby
[J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2009, 237 : 948 - 948

← 1 2 →